Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

Jan de Jong, Donna Skee, Peter Hellemans, James Jiao, Ronald de Vries, Dominique Swerts, Eric Lawitz, Thomas Marbury, William Smith, Juthamas Sukbuntherng, Erik Mannaert

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This open-label, single-dose study was designed to characterize pharmacokinetics and safety profile of ibrutinib in hepatically impaired subjects. Each subject received single oral dose of ibrutinib (140 mg) following an overnight fast (hepatic impairment-mild [n = 6], moderate [n = 10], and severe [n = 8]; healthy control [n = 6]). Subjects with hepatic impairment showed significant increase in ibrutinib plasma exposures and fraction unbound ibrutinib. Compared to control group, mean exposure (AUClast; unbound) in mild, moderate, and severe cohorts was 4.1-, 9.8-, 13.4-fold higher, respectively. Terminal half-life trended slightly longer in moderately and severely impaired subjects, but risk of accumulation on repeated dosing appears negligible as half-life did not exceed 10 h. Based on observed effects on exposure, reduced doses are recommended for patients with mild and moderate liver impairment (Child–Pugh Class A and B), whereas 140 mg is considered too high for severely impaired patients (Class-C). A single dose of 140 mg was well tolerated in this study (NCT01767948).

Original languageEnglish (US)
Pages (from-to)185-194
Number of pages10
JournalLeukemia and Lymphoma
Volume58
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Pharmacokinetics
Liver
Half-Life
Safety
Control Groups
PCI 32765

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

de Jong, J., Skee, D., Hellemans, P., Jiao, J., de Vries, R., Swerts, D., ... Mannaert, E. (2017). Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment* Leukemia and Lymphoma, 58(1), 185-194. https://doi.org/10.1080/10428194.2016.1189548

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment* . / de Jong, Jan; Skee, Donna; Hellemans, Peter; Jiao, James; de Vries, Ronald; Swerts, Dominique; Lawitz, Eric; Marbury, Thomas; Smith, William; Sukbuntherng, Juthamas; Mannaert, Erik.

In: Leukemia and Lymphoma, Vol. 58, No. 1, 02.01.2017, p. 185-194.

Research output: Contribution to journalArticle

de Jong, J, Skee, D, Hellemans, P, Jiao, J, de Vries, R, Swerts, D, Lawitz, E, Marbury, T, Smith, W, Sukbuntherng, J & Mannaert, E 2017, 'Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment* ', Leukemia and Lymphoma, vol. 58, no. 1, pp. 185-194. https://doi.org/10.1080/10428194.2016.1189548
de Jong, Jan ; Skee, Donna ; Hellemans, Peter ; Jiao, James ; de Vries, Ronald ; Swerts, Dominique ; Lawitz, Eric ; Marbury, Thomas ; Smith, William ; Sukbuntherng, Juthamas ; Mannaert, Erik. / Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment* In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 1. pp. 185-194.
@article{850ab102b69f4a35bc2c3982da583bd8,
title = "Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*",
abstract = "This open-label, single-dose study was designed to characterize pharmacokinetics and safety profile of ibrutinib in hepatically impaired subjects. Each subject received single oral dose of ibrutinib (140 mg) following an overnight fast (hepatic impairment-mild [n = 6], moderate [n = 10], and severe [n = 8]; healthy control [n = 6]). Subjects with hepatic impairment showed significant increase in ibrutinib plasma exposures and fraction unbound ibrutinib. Compared to control group, mean exposure (AUClast; unbound) in mild, moderate, and severe cohorts was 4.1-, 9.8-, 13.4-fold higher, respectively. Terminal half-life trended slightly longer in moderately and severely impaired subjects, but risk of accumulation on repeated dosing appears negligible as half-life did not exceed 10 h. Based on observed effects on exposure, reduced doses are recommended for patients with mild and moderate liver impairment (Child–Pugh Class A and B), whereas 140 mg is considered too high for severely impaired patients (Class-C). A single dose of 140 mg was well tolerated in this study (NCT01767948).",
author = "{de Jong}, Jan and Donna Skee and Peter Hellemans and James Jiao and {de Vries}, Ronald and Dominique Swerts and Eric Lawitz and Thomas Marbury and William Smith and Juthamas Sukbuntherng and Erik Mannaert",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/10428194.2016.1189548",
language = "English (US)",
volume = "58",
pages = "185--194",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

AU - de Jong, Jan

AU - Skee, Donna

AU - Hellemans, Peter

AU - Jiao, James

AU - de Vries, Ronald

AU - Swerts, Dominique

AU - Lawitz, Eric

AU - Marbury, Thomas

AU - Smith, William

AU - Sukbuntherng, Juthamas

AU - Mannaert, Erik

PY - 2017/1/2

Y1 - 2017/1/2

N2 - This open-label, single-dose study was designed to characterize pharmacokinetics and safety profile of ibrutinib in hepatically impaired subjects. Each subject received single oral dose of ibrutinib (140 mg) following an overnight fast (hepatic impairment-mild [n = 6], moderate [n = 10], and severe [n = 8]; healthy control [n = 6]). Subjects with hepatic impairment showed significant increase in ibrutinib plasma exposures and fraction unbound ibrutinib. Compared to control group, mean exposure (AUClast; unbound) in mild, moderate, and severe cohorts was 4.1-, 9.8-, 13.4-fold higher, respectively. Terminal half-life trended slightly longer in moderately and severely impaired subjects, but risk of accumulation on repeated dosing appears negligible as half-life did not exceed 10 h. Based on observed effects on exposure, reduced doses are recommended for patients with mild and moderate liver impairment (Child–Pugh Class A and B), whereas 140 mg is considered too high for severely impaired patients (Class-C). A single dose of 140 mg was well tolerated in this study (NCT01767948).

AB - This open-label, single-dose study was designed to characterize pharmacokinetics and safety profile of ibrutinib in hepatically impaired subjects. Each subject received single oral dose of ibrutinib (140 mg) following an overnight fast (hepatic impairment-mild [n = 6], moderate [n = 10], and severe [n = 8]; healthy control [n = 6]). Subjects with hepatic impairment showed significant increase in ibrutinib plasma exposures and fraction unbound ibrutinib. Compared to control group, mean exposure (AUClast; unbound) in mild, moderate, and severe cohorts was 4.1-, 9.8-, 13.4-fold higher, respectively. Terminal half-life trended slightly longer in moderately and severely impaired subjects, but risk of accumulation on repeated dosing appears negligible as half-life did not exceed 10 h. Based on observed effects on exposure, reduced doses are recommended for patients with mild and moderate liver impairment (Child–Pugh Class A and B), whereas 140 mg is considered too high for severely impaired patients (Class-C). A single dose of 140 mg was well tolerated in this study (NCT01767948).

UR - http://www.scopus.com/inward/record.url?scp=84994479597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994479597&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1189548

DO - 10.1080/10428194.2016.1189548

M3 - Article

VL - 58

SP - 185

EP - 194

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -